Advanced Age of Renal Transplant Recipients Correlates With Increased Plasma Concentrations of Interleukin-6, Chemokine Ligand 2 (CCL2), and Matrix Metalloproteinase 2, and Urine Concentrations of CCL2 and Tissue Inhibitor of Metalloproteinase 1

2014 ◽  
Vol 46 (8) ◽  
pp. 2640-2643 ◽  
Author(s):  
O. Mazanowska ◽  
M. Żabińska ◽  
K. Kościelska-Kasprzak ◽  
D. Kamińska ◽  
M. Banasik ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Matrix Metalloproteinase ◽  
Plasma Concentrations ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Matrix Metalloproteinase 2 ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Chemokine Ligand ◽  
Urine Concentrations ◽  
Chemokine Ligand 2

scholarly journals Tacrolimus-Based Immunosuppressive Therapy Influences Sex Hormone Profile in Renal-Transplant Recipients—A Research Study

Biology ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 709
Author(s):  
Dagmara Szypulska-Koziarska ◽  
Aleksandra Wilk ◽  
Małgorzata Marchelek-Myśliwiec ◽  
Daria Śleboda-Taront ◽  
Barbara Wiszniewska
Keyword(s):  
Renal Transplant ◽  
Immunosuppressive Therapy ◽  
Follicle Stimulating Hormone ◽  
Plasma Concentrations ◽  
Graft Function ◽  
Hormonal Status ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Study Results ◽  
Stimulating Hormone

It is estimated that approximately 20% of couples suffer from infertility worldwide and within renal-transplant recipients, this problem is 10 times more common. An intake of immunosuppressants may lead to hormonal imbalance. The aim of the study was to investigate the influence of tacrolimus-based therapy on the hormonal status of grafted patients. Blood samples were obtained from patients from the Department of Nephrology, Transplantology, and Internal Medicine of Independent Public Clinical Hospital No. 2, Pomeranian Medical University. All 121 patients had stable graft function for over 6 months. The blood plasma concentrations of luteinizing hormone, follicle-stimulating hormone, prolactin, testosterone, estradiol, cortisol were assessed by the electrochemiluminescence method. We observed decreased levels of prolactin (11.9 ng/mL) and cortisol (87.4 μg/mL) in patients under tacrolimus-based therapy. Tacrolimus-based therapy was also associated with increased testosterone and follicle-stimulating hormone in males, 4.04 ng/mL and 6.9 mLU/mL, respectively, and decreased testosterone levels in females, 0.121 ng/mL. We also assessed that immunosuppressive therapy based on tacrolimus is less nephrotoxic in comparison to other regimens. Concluding, tacrolimus-based therapy may influence the hormonal status of transplant recipients in the current study. Results presented here are believed to be helpful for clinicians and patients, especially within the aspect of willingness for biological offspring.

scholarly journals Influence ofNAT2Polymorphisms on Sulfamethoxazole Pharmacokinetics in Renal Transplant Recipients

2011 ◽  
Vol 56 (2) ◽  
pp. 825-829 ◽  
Author(s):  
Hideaki Kagaya ◽  
Masatomo Miura ◽  
Takenori Niioka ◽  
Mitsuru Saito ◽  
Kazuyuki Numakura ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Side Effects ◽  
Renal Transplant ◽  
Plasma Concentrations ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Slow Acetylator ◽  
Drug Concentrations ◽  
Acetylator Genotype ◽  
The Impact

ABSTRACTThe sulfamethoxazole (SMX)-trimethoprim drug combination is routinely used as prophylaxis againstPneumocystispneumonia during the first 3 to 6 months after renal transplantation. The objective of this study was to examine the impact ofN-acetyltransferase 2 (NAT2) andCYP2C9polymorphisms on the pharmacokinetics of SMX in 118 renal transplant recipients. Starting on day 14 after renal transplantation, patients were administered 400 mg/day-80 mg/day of SMX-trimethoprim orally once daily. On day 14 after the beginning of SMX therapy, plasma SMX concentrations were determined by a high-performance liquid chromatography method. The SMX area under the concentration-time curve from 0 to 24 h (AUC0-24) for 15 recipients with theNAT2slow acetylator genotype (NAT2*5/*6, -*6/*6, -*6/*7, and -*7/*7) was significantly greater than that for 56 recipients with theNAT2rapid acetylator genotype (homozygous forNAT2*4) (766.4 ± 432.3 versus 537.2 ± 257.5 μg-h/ml, respectively;P= 0.0430), whereas there were no significant differences in the SMX AUC0-24between theCYP2C9*1/*1and -*1/*3groups. In a multiple regression analysis, the SMX AUC0-24was associated withNAT2slow acetylator polymorphisms (P= 0.0095) and with creatinine clearance (P= 0.0499). Hepatic dysfunction inNAT2slow acetylator recipient patients during the 6-month period after SMX administration was not observed. SMX plasma concentrations were affected byNAT2polymorphisms and renal dysfunction. Although standard SMX administration to patients withNAT2slow acetylator polymorphisms should be accompanied by monitoring for side effects and drug interaction effects from the inhibition of CYP2C9, SMX administration at a low dose (400 mg) as prophylaxis may not provide drug concentrations that reach the level necessary for the expression of side effects. Further studies with a larger sample size should be able to clarify the relationship between SMX plasma concentration and side effects.

scholarly journals A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine.

1993 ◽  
Vol 3 (12) ◽  
pp. 1884-1891
Author(s):  
A K Cheung ◽  
G A DeVault ◽  
M C Gregory
Keyword(s):  
Renal Transplant ◽  
Low Density Lipoprotein ◽  
Plasma Concentrations ◽  
Density Lipoprotein ◽  
Normal Subjects ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Cardiovascular Morbidity And Mortality

Hypercholesterolemia occurs commonly in renal transplant recipients and may contribute to the high cardiovascular morbidity and mortality in these patients. Although an effective hypolipidemic agent, lovastatin has been associated with rhabdomyolysis and acute renal failure in patients on cyclosporin A (CsA). In this study, lovastatin was administered at 10 mg/day for 8 wk followed by 20 mg/day for 12 wk to six renal transplant recipients who were receiving CsA concomitantly. The 10-mg/day dose was effective, but an additional lipid-lowering effect was seen with the 20-mg/day dose. Both serum total cholesterol and low-density lipoprotein cholesterol levels decreased by 27% at the end of the 20 wk of lovastatin administration. Serum high-density lipoprotein cholesterol and triglyceride levels remained unchanged. No significant clinical or laboratory adverse effects were observed, including muscular symptoms, ophthalmologic abnormalities, or alterations in serum creatine kinase, urea nitrogen, creatinine, transaminases, and CsA levels. Peak and trough plasma concentrations of active lovastatin were comparable to those reported in normal subjects receiving a higher lovastatin dose without CsA. It was concluded that the administration of low-dose (10 to 20 mg/day) lovastatin to renal transplant recipients receiving concomitant CsA can be safe and effective in lowering serum cholesterol.

Sign in / Sign up

Export Citation Format

Share Document